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OBJECTIVES This study was designed to compare the in-hospital outcome of patients presenting with 12 h
from onset of chest pain and acute ST elevation myocardial infarction (AMI) who received
either immediate invasive or conservative therapy.
BACKGROUND The benefits of fibrinolytic therapy diminish in patients presenting with AMI and onset of
chest pain 12 h. Primary angioplasty has been suggested as a possible treatment for such
patients, but they have been excluded from most trials of primary angioplasty. It remains
unclear if an invasive treatment strategy is beneficial to these patients.
METHODS Patients presenting with 12 h of chest pain and AMI were identified from the National
Registry of Myocardial Infarction 2 database. Patients receiving invasive therapy 6 h after
hospital admission were compared with those receiving conservative therapy. Short-term
outcomes were compared on the basis of the initial therapy received. To help control for
baseline differences in the groups, patients were matched with controls by propensity score
methodology.
RESULTS On preliminary analysis, in-hospital outcome was improved in terms of recurrent ischemia,
angina, myocardial infarction and mortality in patients receiving initial invasive therapy (odds
ratio [OR]  0.67; 95% confidence interval [CI] 0.49 to 0.92 for mortality). After matching
by propensity score, the mortality benefit persisted on bivariate analysis (3.5% vs. 5.0%, p 
0.036), though on multivariate analysis, only a non-significant but strong trend toward
decreased mortality remained (OR  0.73; 95% CI 0.53 to 1.01).
CONCLUSIONS Patients receiving early invasive therapy had lower risk features on presentation. Selection bias
may play an important role in choosing these patients’ course of treatment and their subsequent
outcomes. Certain patients presenting with AMI and duration of chest pain 12 h may benefit
from early invasive therapy. These patients could be characterized in a randomized trial. (J Am
Coll Cardiol 2002;39:826–33) © 2002 by the American College of Cardiology Foundation
Patients presenting with acute ST elevation myocardial
infarction (AMI) and ST-segment elevation on their initial
electrocardiogram (ECG) should be considered for reper-
fusion therapy. This can be achieved by the use of fibrino-
lytic agents or invasively through the use of coronary
angiography and subsequent percutaneous transluminal cor-
onary angioplasty (PTCA) or coronary artery bypass graft
(CABG) surgery. A substantial number of patients with AMI
have relative or absolute contraindications to fibrinolysis, and
many of these patients receive primary PTCA. The most
common reasons given for fibrinolytic ineligibility in patients
presenting with ST elevation AMI are advanced age, stroke or
bleeding risk and presentation with6 h of chest pain (1). The
time to administration of fibrinolytic therapy is a major factor
in reducing mortality, with the degree of benefit decreasing
sharply when 12 h of chest pain is present (2). Indeed, the
American College of Cardiology/American Heart Association
Practice Guidelines for the Management of Patients with
Acute Myocardial Infarction considers the administration of
fibrinolytic therapy to patients presenting12 h after onset of
chest pain a Class IIb (or less well established) indication (3).
Although there is a Class I indication for primary PTCA or
CABG surgery in this setting, there are few objective data to
support this recommendation.
Because no randomized trials have been published, the
only way to compare outcomes of patients who are
fibrinolytic-ineligible because of chest pain for 12 h and
receive either primary PTCA or no immediate reperfusion
therapy would be an observational study. The National
Registry of Myocardial Infarction provides an ideal database
with which to study this issue.
METHODS
Patient population. Patients presenting 12 h after onset
of chest pain with ST-segment elevation on their initial
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ECG and no other contraindications to fibrinolytic therapy
were identified from the National Registry of Myocardial
Infarction 2 (NRMI 2) database. The NRMI is a multi-
center, ongoing observational study designed to collect
demographic, clinical, treatment and outcome data on
patients with acute myocardial infarction (MI). The NRMI
2 collected data from 1,482 hospitals from 1994 through
1998 and included 772,586 patients. Hospitals were encour-
aged to enroll consecutive patients, regardless of treatment
strategy. Because the NRMI is an anonymous observational
study, no informed consent is required of participating
patients by the institutional review boards at any of the
participating institutions. All patients were diagnosed with
MI as defined by either: 1) a history and presentation
suggestive of MI accompanied by (a) total creatine kinase
(CK) or CK-MB greater than or equal to twice the upper
limit of the hospital laboratory normal or (b) electrocardio-
graphic evidence of MI or (c) in the absence of definitive
cardiac enzyme or electrocardiographic data, alternative
enzymatic, scintigraphic, echocardiographic, angiographic
or autopsy evidence of MI; or 2) an International Classifi-
cation of Diseases, 9th revision, clinical modification dis-
charge diagnosis code for AMI, 410.01 through 410.91.
Patients were excluded from the study if they either: 1) were
transferred from the NRMI 2 hospital; 2) received fibrino-
lytic therapy; 3) were in cardiogenic shock (Killip class IV);
or 4) were treated in hospitals that could not perform
coronary angiography, angioplasty and/or CABG surgery.
Study variables included in this analysis are listed in Table
1. Patients who received initial invasive therapy were de-
fined as those who underwent cardiac catheterization,
PTCA or CABG within 6 h of presentation to the hospital.
Statistical analysis. All analyses were performed using
SAS Version 8.0 (SAS Institute, Cary, North Carolina).
Differences between the patients who received initial inva-
sive therapy and those who received conservative therapy
were evaluated with the Student t test for continuous
variables and the chi-square test for categorical variables. A
stepwise, multivariate logistic regression analysis was per-
formed to predict hospital mortality. The following vari-
ables were chosen as independent predictors of hospital
mortality and allowed to enter the model: age, gender, white
race, history of MI, history of congestive heart failure
(CHF), previous PTCA, previous CABG surgery, diabetes
mellitus, smoking history, Killip class, pulse 100 beats/
min, systolic blood pressure 100 mm Hg, time from
symptom onset to first ECG, the use of aspirin, intravenous
unfractionated heparin, intravenous or oral beta-blockers,
calcium channel blockers (all medications within the first
24 h) and anterior location of MI. An indicator variable for
initial invasive therapy versus conservative therapy was
forced into the model. Odds ratios (OR) and 95% confi-
dence intervals (CI) were calculated.
Because of the substantial differences in baseline charac-
teristics between the treatment groups, propensity score
methodology was used to identify comparable patients
treated with each strategy. The propensity score was initially
proposed by Rosenbaum and Rubin (4) and has been used in
prior observational studies to help adjust for treatment
selection bias (5,6).
In this study, the treatment selection is for initial invasive
therapy, and factors that predicted which patients were
significantly (p  0.05) more likely to receive this treatment
were first identified. These included white race, previous
PTCA, chest pain at presentation and admission diagnosis
of MI. Factors that predicted which patients were signifi-
cantly (p  0.05) less likely to receive invasive therapy were
also identified and included older age, history of prior MI,
history of CHF, being transferred in from an outside
hospital and hospital discharge in 1994, 1995 or 1996 (when
compared with 1997 as the reference year). A stepwise,
multivariate logistic regression analysis was then performed
to predict initial invasive therapy. The predicted probability
of receiving initial invasive therapy (the propensity score)
was calculated for each patient. Patients with the same
propensity score in either treatment group therefore had the
same probability of receiving initial invasive therapy based
on the factors identified above. Patients receiving initial
invasive therapy (cases) were then matched to patients
receiving conservative therapy (controls) on propensity score
using the nearest available pair matching method. If more
then one unmatched control matched to a case, the control
was selected at random. Cases were first matched on five
digits of the propensity score. For those that were left
unmatched, matching continued on four digits, then three,
then two and then one digit of the propensity score. Ninety
percent of the cases matched to a control. Bivariate differ-
ences between the matched pairs were evaluated using the
signed tank test for continuous data and the McNemar’s test
for binary data. After the matched-pair analysis, the original
multivariate logistic regression model to predict hospital
death was re-run with the propensity score forced in. Odds
ratios and 95% CIs were calculated.
Abbreviations and Acronyms
AMI  acute ST elevation myocardial infarction
CABG  coronary artery bypass grafting
CHF  congestive heart failure
CI  confidence interval
CK  creatine kinase
ECG  electrocardiogram
GUSTO  Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded
Coronary Arteries
MI  myocardial infarction
NRMI  National Registry of Myocardial Infarction
OR  odds ratio
PAMI  Primary Angioplasty in Myocardial
Infarction
PTCA  percutaneous transluminal coronary
angioplasty
TIMI  Thrombolysis In Myocardial Infarction
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RESULTS
A total of 7,358 patients met inclusion criteria for this study
(Table 1). From this group 1,631 patients (22%) were
treated with initial invasive therapy and 5,727 (78%) re-
ceived conservative therapy. Of the patients in the invasive
group, 1,290 (79%) had primary PTCA.
Patients in the invasive group were younger, more likely
to be men, more likely white and more likely to have had a
history of smoking and prior PTCA (Table 1). They were
less likely to have had a prior history of CHF, diabetes
mellitus or CABG. Although presenting systolic blood
pressure was similar between the two groups, patients who
received invasive therapy were less likely to be tachycardic,
more likely to be in Killip class I and had lower risk MI
features, as defined by the Thrombolysis In Myocardial
Infarction (TIMI) (7) and Primary Angioplasty in Myocar-
dial Infarction (PAMI) (8) trials (Table 1).
Patients in the invasive group were more likely to receive
intravenous heparin, aspirin and intravenous beta-blockers.
They were less likely to receive oral beta-blockers. There
was no statistically significant difference in the use of
calcium channel blockers.
The number of procedures, complications and clinical
outcomes of both patient groups is shown in Table 2.
Patients in the invasive therapy group were less likely to
have recurrent ischemia or angina and recurrent MI than
the patients receiving conservative therapy. There was no
significant difference in the incidence of stroke between the
two groups. Major bleeding (causing hemodynamic com-
promise) was more likely to occur in the patients who
underwent initial invasive therapy (Table 2). It should be
noted that 72% of the patients in the conservative therapy
group eventually underwent cardiac catheterization during
their initial hospitalization, but most of these procedures
occurred 24 h after the onset of chest pain.
Comparison of groups matched by propensity analysis.
As expected, baseline differences between the treatment
groups were less pronounced when the patients were
matched using the propensity score. As shown in Table 3,
patients receiving conservative therapy were more likely to




(n  5,727) p Value
Age (yrs, mean) 61.1  12.91 65.7  13.75  0.001
Gender, no. (%)
Female 535 (32.8) 2,227 (38.9)  0.001
Male 1,096 (67.2) 1,204 (61.1)
Race: white, no. (%) 1,354 (87.7) 2,440 (85.0) 0.008
Medical history, no. (%)
Angina 179 (11.0) 761 (13.3) 0.014
Myocardial infarction 207 (12.7) 961 (16.8)  0.001
Congestive heart failure 49 (3.0) 437 (7.6)  0.001
CABG 84 (5.2) 415 (7.2) 0.003
PTCA 118 (7.2) 302 (5.3) 0.003
Diabetes mellitus 390 (23.9) 1,526 (26.6) 0.026
Smoking 665 (40.8) 1,814 (31.7)  0.001
Presentation, no. (%)
Time to first ECG (h)* 19.98  7.55 21.87  8.40  0.001
Pulse 100 beats/min 264 (16.3) 1,087 (19.3) 0.007
Systolic BP 100 mm Hg 103 (6.4) 356 (6.3) NS
Killip class†
Class I 1,416 (87.2) 4,568 (80.3)
Class II 166 (10.2) 840 (14.8)  0.001
Class III 42 (2.6) 278 (4.9)  0.001
PAMI high risk‡ 991 (61.0) 3,868 (68.0)  0.001
TIMI high risk§ 1,051 (64.4) 4,114 (71.8)  0.001
Non–Q-wave MI 275 (16.9) 1,444 (25.2)  0.001
Medications within 24 h of diagnosis of MI, no. (%)
IV heparin 1,549 (95.0) 4,947 (86.4)  0.001
Aspirin 1,487 (91.2) 4,945 (86.3)  0.001
IV beta-blocker 371 (22.7) 947 (16.5)  0.001
Oral beta-blocker 610 (37.4) 2,553 (44.6)  0.001
Calcium channel blocker 182 (11.2) 674 (11.8) NS
Plus-minus values are means  standard deviation.
*Time to ECG Time from symptom onset to initial electrocardiogram. †Killip class I no signs of CHF. Class II third
heart sound, rales and radiographic evidence of CHF. Class III  pulmonary edema. Reference group for univariate analysis is
Killip class I. ‡PAMI high risk  anterior ST elevation or age 70 years or pulse 100 (see reference 9). §TIMI high risk 
age 70 years old or history of MI or presentation of CHF (Killip Class II and III) or anterior MI location or the combination
of pulse 100 beats/min and systolic blood pressure 100 mm Hg (see reference 8).
CHF congestive heart failure; CABG coronary artery bypass graft; ECG electrocardiogram; IV intravenous; MI
myocardial infarction; NS  not significant; PTCA  percutaneous transluminal coronary angioplasty; PAMI  Primary
Angioplasty In Myocardial Infarction; TIMI  Thrombolysis In Myocardial Infarction.
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have had a slightly longer duration of chest pain and had
higher rates of non–Q-wave MI. They were less likely to
receive intravenous heparin and more likely to receive oral
beta-blockers. Excluding these factors, there were no other
statistically significant (p  0.05) differences between the
groups.
The number of procedures, complications and clinical
outcomes of both patient groups matched by propensity
score is shown in Table 4. Similar proportions of patients
underwent coronary angiography, PTCA and CABG as in
the non-propensity score matched groups. In addition, the
rates of complications and the clinical outcomes were also
similar. The lower rate of recurrent ischemia in the invasive
therapy group remained statistically significant; however,
the previously seen improvement in the rate of recurrent MI
was no longer statistically significant.
Hospital mortality. In the non-propensity analysis, unad-
justed hospital mortality was significantly lower in patients
treated with invasive therapy (3.4% vs. 6.6%, p 0.001). To
help adjust for baseline differences between patient groups,
we performed multivariate logistic regression models (Fig.
1). Factors associated with higher hospital mortality in-
cluded older age (OR  1.70 per 10-year increment; 95%
CI 1.54 to 1.89), prior history of CHF (OR  1.373; 95%
CI 1.01 to 1.87), presentation in Killip class II (OR 2.01;
95% CI 1.56 to 2.58) and presentation in Killip class III
(OR  1.84; 95% CI 1.26 to 2.7). Patients presenting with
systolic blood pressure 100 mm Hg (OR  3.15; 95% CI
2.33 to 4.27), or pulse 100 beats/min (OR  1.69; 95%
CI 1.33 to 2.15) also had higher hospital mortality. Lower
hospital mortality was seen in patients who smoked (OR 
0.70; 95% CI 0.52 to 0.94) received aspirin (OR  0.57;
95% CI 0.44 to 0.74) or received oral beta-blockers (OR 
0.61; 95% CI 0.48 to 0.77) within 24 h of the diagnosis of
MI. Patients with non–Q-wave MI also had lower mortality
(OR  0.64; 95% CI 0.49 to 0.83). After adjustment for
these factors, there remained an association between receiv-
ing initial invasive therapy and lower hospital mortality
(OR  0.67; 95% CI 0.49 to 0.92).
Hospital mortality in the groups matched by propensity
analysis. In the groups matched by propensity analysis, the
unadjusted hospital mortality remained significantly lower
in patients treated with invasive therapy (3.5% vs. 5.0%, p
0.036). After matching by propensity score, the odds ratios
for older age, Killip classes, pulse 100 beats/min, and
systolic blood pressure 100 mm Hg continued to predict
higher mortality for patients with these factors (OR all 1,
Fig. 2). The favorable odds ratios for smoking status,
aspirin, oral beta-blockers and non–Q-wave MI also per-
Table 2. Procedures, Complications and Clinical Outcomes of







(n  5,727) p Value
Procedures, no. (%)
Coronary angiography 1,629 (99.9) 4,111 (71.8)  0.001
PTCA 1,290 (79.1) 1,630 (28.5)  0.001
CABG 247 (15.1) 961 (16.8) NS
Complications, no. (%)
Stroke 14 (0.9) 64 (1.1) NS
Hemorrhagic 1 (0.1) 8 (0.1) NS
Non-hemorrhagic 13 (0.8) 56 (1.0) NS
Major bleeding 46 (2.8) 87 (1.5)  0.001
At hospital discharge
Ejection fraction (%) 45.9  12.80 45.3  13.17 NS
Anterior MI location, no. (%) 673 (41.3) 2,203 (38.5) 0.041
Clinical outcomes, no. (%)
Recurrent ischemia or angina 175 (10.7) 793 (13.8) 0.001
Recurrent MI 20 (1.2) 126 (2.2) 0.013
Death 55 (3.4) 380 (6.6)  0.001
*Plus-minus values are means  standard deviation.
Abbreviations as in Table 1.
Table 3. Patient Characteristics of Invasive Therapy and







(n  1,470) p Value
Age (yrs, mean) 61.2  12.97 61.0  13.96 NS
Gender, no. (%)
Female 490 (33.3) 491 (33.4) NS
Male 980 (66.7) 979 (66.6)
Race, white, no. (%) 1,292 (87.9) 1,279 (87.0) NS
Medical history, no. (%)
Angina 161 (11.0) 177 (12.0) NS
Myocardial infarction 186 (12.7) 199 (13.5) NS
Congestive heart failure 45 (3.1) 47 (3.2) NS
CABG 76 (5.2) 101 (6.9) 0.052
PTCA 106 (7.2) 110 (7.5) NS
Diabetes mellitus 355 (24.1) 388 (26.4) NS
Smoking 597 (40.6) 548 (37.3) NS
Presentation, no. (%)
Time to first ECG (h)* 19.94  7.55 21.57  8.17  0.001
Pulse 100 beats/min 250 (17.0) 285 (19.4) NS
Systolic BP 100 mm Hg 99 (6.7) 93 (6.3) NS
Killip class†
Class I 1,289 (87.7) 1,266 (86.1)
Class II 143 (9.7) 151 (10.3) NS
Class III 38 (2.6) 53 (3.6) NS
PAMI high risk‡ 891 (60.6) 875 (59.5) NS
TIMI high risk§ 941 (64.0) 910 (61.9) NS
Non–Q-wave MI 251 (17.1) 320 (21.8) 0.001
Medications within 24 h
of diagnosis of MI,
no. (%)
IV heparin 1,394 (94.8) 1,319 (89.7)  0.001
Aspirin 1,341 (91.2) 1,310 (89.1) 0.055
IV beta-blocker 334 (22.7) 311 (21.2) NS
Oral beta-blocker 553 (37.6) 745 (50.7)  0.001
Calcium channel blocker 165 (11.2) 142 (9.7) NS
Plus-minus values are means  standard deviation.
*Time to ECG  Time from symptom onset to initial electrocardiogram. †Killip
class I  no signs of CHF. Class II  third heart sound, rales and radiographic
evidence of CHF. Class III  pulmonary edema. Reference group for univariate
analysis is Killip class I. ‡PAMI high risk  anterior ST elevation or age 70 years
or pulse 100 (see reference 9). §TIMI high risk  age 70 years old or history of
MI or presentation of CHF (Killip Class II and III) or anterior MI location or the
combination of pulse 100 beats/min and systolic blood pressure 100 mm Hg (see
reference 8).
Abbreviations as in Table 1.
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sisted (OR  1.0, Fig. 2). A history of CHF was no longer
associated with increased mortality and dropped out of the
multivariate analysis with a neutral effect on hospital mor-
tality. There was a trend toward decreased hospital mortality
in patients receiving initial invasive therapy (OR 0.731), and
although its CI of 95%—which just crossed 1.0 (range 0.529
to 1.009)—was not statistically significant, it suggests a
strong trend favoring an early invasive strategy.
DISCUSSION
On preliminary analysis, these findings suggest that an
initial invasive approach may be more beneficial than
medical therapy alone in patients presenting with chest pain
for 12 h and ST elevation AMI. A statistically significant
mortality benefit was apparent in patients who received
invasive therapy within 6 h of hospital presentation with a
nearly twofold increase in survival to hospital discharge.
This effect persisted on multivariate logistic regression
analysis. After subject matching based on their propensity to
receive invasive therapy, patients in the invasive therapy
group still had lower rates of recurrent ischemia. Although
the rates of recurrent MI and in-hospital mortality remained
lower in the invasive therapy group, these were no longer
statistically significant when compared with rates for pro-
pensity score matched patients who received only medical
therapy, though a strong trend was present.
Patients in the invasive therapy group were less likely to
have had prior histories of diabetes mellitus, MI, CHF and
CABG; they were more likely to have had prior PTCA and
more likely to have been smokers. Aside from a history of
CABG, these differences were no longer statistically signif-
icant after matching by propensity score. These findings
indicate that selection bias may play a significant role in
Table 4. Procedures, Complications and Clinical Outcomes of
Patients at Hospital Discharge in Invasive and Conservative






(n  1,470) p Value
Procedures, no. (%)
Coronary angiography 1,468 (99.9) 1,109 (75.4)  0.001
PTCA 1,156 (78.6) 432 (29.4)  0.001
CABG 221 (15.0) 247 (16.8) NS
Complications, no. (%)
Stroke 14 (1.0) 12 (0.8) NS
Hemorrhagic 1 (0.1) 0 (0.0) NS
Non-hemorrhagic 13 (0.9) 12 (0.8) NS
Major bleeding 42 (2.9) 20 (1.4) 0.005
At hospital discharge
Ejection fraction (%) 45.5  12.68 45.7  12.50 NS
Anterior MI location,
no. (%)
601 (40.9) 519 (35.3) 0.002
Clinical outcomes, no. (%)
Recurrent ischemia
or angina
159 (10.8) 215 (14.6) 0.002
Recurrent MI 19 (1.3) 25 (1.7) NS
Death 51 (3.5) 74 (5.0) 0.036
Plus-minus values are means  standard deviation.
Abbreviations as in Table 1.
Figure 1. Effect of clinical factors on in-hospital mortality (initial analysis). Only those clinical factors that had a statistically significant impact on mortality
are shown. An odds ratio of 1 indicates that the factor is associated with decreased in-hospital mortality. An odds ratio 1 indicates increased in-hospital
mortality. bpm  beats per minute; CHF  congestive heart failure; MI  myocardial infarction; SBP  systolic blood pressure.
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determining the choice of therapy and outcome in this
group of patients.
Of interest, patients in the medical therapy group ap-
peared to be more acutely ill upon presentation, with more
in Killip Class II and in either TIMI or PAMI high-risk
subsets. Physician bias may favor initial invasive therapy in
lower risk patients. The patients in the invasive therapy
group also received more complete medical therapy than
patients in the conservative therapy group. A significantly
larger proportion of patients in the invasive therapy group
received aspirin, heparin and (intravenous but not oral)
beta-blockers. Both aspirin (9) and beta-blockade (10) have
been shown to significantly decrease AMI mortality, which
might explain at least a portion of the mortality benefit seen
in our data. Thus, although the early use of invasive therapy
may lead to substantial benefits in the care of patients with
AMI, it may also be a marker for the use of other beneficial
therapies. Indeed, the use of invasive therapy would cer-
tainly require the involvement of cardiologists, who have
been shown to be more likely than non-cardiologists to
utilize beneficial medical therapies (11).
Timing and fibrinolyis. On the basis of findings from
large randomized trials, most clinicians have limited the use
of fibrinolytic therapy to patients who present within 12 h of
the onset of chest pain. The Fibrinolytic Therapy Trialists’
Collaborative Group reviewed the data from nine trials that
randomized more than 1,000 patients with suspected MI
between fibrinolytic therapy and control (2). An excess of
deaths was noted in patients presenting with12 h of chest
pain since symptom onset, and statistically uncertain overall
mortality benefit was seen for those presenting at 13 to 18 h.
The Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries
(GUSTO-I) investigators similarly noted increasing mor-
tality, as well as an increase in the frequency of shock, heart
failure and stroke with increasing delay in the administra-
tion of fibrinolytic therapy (12). Thus, a perceived risk to
benefit quotient has evolved that favors fibrinolysis until
12 h of chest pain, with the perceived risks outweighing the
benefit for patients presenting with more prolonged chest
pain.
Timing and angioplasty. Primary PTCA has compared
favorably with fibrinolytic therapy in the treatment of AMI
in a number of randomized controlled trials (8,13,14).
These trials largely excluded patients who were fibrinolytic
ineligible for various reasons, with the presence of chest pain
for 12 h among them. Although it is widely assumed that
these patients benefit from late reperfusion therapy with
PTCA, this issue has not been well studied. A study of 139
patients presenting with 6 to 48 h of chest pain with a
median time to angioplasty of 15 h found a 5.5% in-hospital
mortality rate in patients who had successful primary PTCA
(15). Mortality was substantially higher when angioplasty
was unsuccessful, or when performed in the presence of
cardiogenic shock, advanced age or an ejection fraction
30%. However, there was no control group in this trial.
The MATE trial (Medicine vs. Angiography in Throm-
bolytic Exclusion) randomized fibrinolytic ineligible pa-
tients with acute coronary syndromes to early triage angiog-
raphy versus conventional medical therapy (16). The
Figure 2. Effect of clinical factors on in-hospital mortality (patients matched by propensity to have invasive therapy). Only those clinical factors that had
a statistically significant impact on mortality are shown. An odds ratio of 1 indicates that the factor is associated with decreased in-hospital mortality.
An odds ratio 1 indicates increased in-hospital mortality. Abbreviations as in Figure 1.
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majority of patients were ineligible for fibrinolysis because of
ECG ineligibility (lack of ST elevation). However, approx-
imately half of the patients were ineligible because they
presented with chest pain for 6 h. There was no statisti-
cally significant in-hospital mortality benefit, though the
composite in-hospital end point of recurrent ischemia,
reinfarction or death was statistically significant, with a
benefit seen for the triage angiography group. There was no
statistically significant benefit in the composite end point of
recurrent infarction or death on long-term follow-up.
A study of the importance of time to reperfusion in 1,352
consecutive patients with AMI treated by primary angio-
plasty included 275 patients who underwent primary PTCA
6 h after symptom onset (17). Although the recovery of
left ventricular function decreased with increasing reperfu-
sion time, patients treated after 6 h of chest pain had
recovery of left ventricular function that was better than
expected. This was felt to be secondary to an increased
incidence of collateral flow to the infarct region, a viewpoint
that is supported by data from other trials (18,19). Primary
angioplasty 6 h after the onset of chest pain appears to
prevent left ventricular dilatation, facilitates favorable ven-
tricular remodeling and possibly prevents the onset of heart
failure in the long run (20,21).
The presence of persistent or stuttering chest pain also
appears to influence the subsequent benefit of late primary
PTCA. One study reported on a small group of patients
who were felt to have persistent perfusion to the infarct zone
and underwent primary PTCA within 24 h of presentation
(18). Ejection fraction rose significantly in these patients
after the procedure, and nearly 70% had residual flow to the
infarct zone whether from the infarct-related artery or by
collaterals.
A recent report from two German databases compared
outcomes in patients receiving primary angioplasty versus
conservative management in patients with AMI and a
pre-hospital delay between 12 and 24 h (22). The study
reported on only 94 patients in the primary angioplasty
group, and an initial mortality benefit seen on univariate
analysis was no longer statistically significant after multiple
logistic regression. The authors attributed the loss of statis-
tical significance to either inadequate study power or a
selection bias. Our data report on a much larger cohort, and
indeed, the multivariate analysis still showed a statistically
significant mortality benefit. However, once we controlled
for selection bias with the propensity analysis, our results too
were no longer statistically significant.
Study limitations. There are several limitations to our
study. The NRMI database is an observational study,
collecting data from various hospitals across the U.S. Inher-
ent to this are issues relating to retrospective collection and
analysis of data, differences in physician practice and report-
ing as well as the subjective nature of some of the presenting
and outcome measurements. Several important measures of
patient outcome were either not collected or not available
for inclusion in this study. These include socioeconomic
status, amount and fluctuation of ST elevation and chest
pain, measurement of troponin T or I and the use of newer
agents such as low-molecular-weight heparins, glycoprotein
IIb/IIIa inhibitors and stents. Several of these measures
have been shown to influence subsequent patient outcome
and prognosis. In addition, no long-term follow-up was
available for this analysis, because the NRMI database
includes only in-hospital data.
Conclusions. We observed an association between invasive
therapy and lower hospital mortality in patients presenting
late with 12 h of chest pain and AMI. Patients receiving
invasive therapy had lower risk features on presentation,
perhaps as a result of physician bias, and received better
medical therapy, perhaps as a result of specialist care. The
mortality benefit persisted after multivariate logistic regres-
sion analysis, and though it was not statistically significant,
a strong trend remained after subject matching by propen-
sity to receive invasive therapy. Primary angioplasty may be
beneficial in certain patients presenting late after onset of
chest pain, but this clinically important hypothesis should
be tested in a randomized prospective trial.
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